Safety of artemisinins in first trimester of prospectively followed pregnancies: An observational study

The Lancet Infectious Diseases

Volumn 16, Issue 5, 2016, Pages 576-583

  Moore, Kerryn A ^a,b   Simpson, Julie A ^a   Paw, Moo Kho ^c   Pimanpanarak, MuPawJay ^c   Wiladphaingern, Jacher ^c   Rijken, Marcus J ^c   Jittamala, Podjanee ^d   White, Nicholas J ^d,e   Fowkes, Freya J I ^a,b,f   Nosten, François ^c,e   McGready, Rose ^c,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; CHLOROQUINE; CLINDAMYCIN; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CONGENITAL MALFORMATION; DRUG EFFECT; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PLASMODIUM VIVAX MALARIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; RANK SUM TEST; RECURRENT INFECTION; SPONTANEOUS ABORTION; ABORTION, SPONTANEOUS; CHEMICALLY INDUCED; MALARIA, FALCIPARUM; MALARIA, VIVAX; PREGNANCY; PREGNANCY COMPLICATION; THAILAND;

ABORTION, SPONTANEOUS; ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; QUININE; THAILAND;

EID: 84957916688     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00547-2     Document Type: Article

References (31)

1. Huynh B-T, Cottrell G, Cot M, Briand V Burden of malaria in early pregnancy: a neglected problem?. Clin Infect Dis 2015, 60:598-604.
2. Dellicour S, ter Kuile FO, Stergachis A Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries. PLoS Med 2008, 5:e187.
3. McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 2011, 12:388-396.
4. Walker PGT, Griffin JT, Cairns M, et al. A model of parity-dependent immunity to placental malaria. Nat Commun 2013, 4:1609.
5. McGready R, Boel M, Rijken MJ, et al. Effect of early detection and treatment on malaria related maternal mortality on the north-western border of Thailand 1986-2010. PLoS One 2012, 7:e40244.
6. Guidelines for the treatment of malaria 2015, WHO, World Health Organization, Geneva. 3rd edition.
7. Clark R Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod Toxicol 2009, 28:285-296.
8. White TEK, Clark RL Sensitive periods for developmental toxicity of orally administered artesunate in the rat. Birth Defects Res B Dev Reprod Toxicol 2008, 83:407-417.
9. Dellicour S, Desai M, Aol G, et al. Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya. Malar J 2015, 14:461.
10. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PLoS One 2014, 9:e84976.
11. Mosha D, Mazuguni F, Mrema S, Sevene E, Abdulla S, Genton B Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort. Malar J 2014, 13:197.
12. Dellicour S, Brasseur P, Thorn P, et al. Probabilistic record linkage for monitoring the safety of artemisinin-based combination therapy in the first trimester of pregnancy in Senegal. Drug Saf 2013, 36:505-513.
13. Rulisa S, Kaligirwa N, Agaba S, Karema C, Mens PF, de Vries PJ Pharmacovigilance of artemether-lumefantrine in pregnant women followed until delivery in Rwanda. Malar J 2012, 11:225.
14. Manyando C, Mkandawire R, Puma L, et al. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar J 2010, 9:249.
15. Adam I, Elhassan EM, Omer EM, Abdulla MA, Mahgoub HM, Adam GK Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. Ann Trop Med Parasitol 2009, 103:205-210.
16. Adam I, Elwasila E, Alnour D, Ali M, Elansari E, Idris M Artemether in the treatment of falciparum malaria during pregnancy in eastern Sudan. Trans R Soc Trop Med Hyg 2004, 98:509-513.
17. Deen J, von Seidlein L, Pinder M, Walraven G, Greenwood B The safety of the combination during pregnancy artesunate and pyrimethamine-sulfadoxine given. Trans R Soc Trop Med Hyg 2001, 95:424-428.
18. Willcox ML, Burton S, Oyweka R, Namyalo R, Challand S, Lindsey K Evaluation and pharmacovigilance of projects promoting cultivation and local use of Artemisia annua for malaria. Malar J 2011, 10:84.
19. Nosten F, ter Kuile F, Maelankirri L, Decludt B, White NJ Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg 1991, 85:424-429.
20. McGready R, Thwai K, Cho T, et al. The effects of quinine and chloroquine trimester of pregnancy antimalarial treatments in the first centred around the potential for auditory nerve damage. Trans R Soc Trop Med Hyg 2002, 96:180-184.
21. Nosten F, Vincenti M, Simpson J, et al. The effects of mefloquine treatment in pregnancy. Clin Infect Dis 1999, 28:808-815.
22. McGready R, Cho T, Keo NK, et al. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis 2001, 33:2009-2016.
23. Moore KA, Simpson JA, Thomas KH, et al. Estimating gestational age in late presenters to antenatal care in a resource-limited setting on the Thai-Myanmar border. PLoS One 2015, published online June 26. 10.1371/journal.pone.0131025.
24. Doubilet PM, Benson CB, Bourne T, Blaivas M Diagnostic criteria for nonviable pregnancy early in the first trimester. N Engl J Med 2013, 369:1443-1451.
25. Scheuerle A, Tilson H Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. Pharmacoepidemiol Drug Saf 2002, 11:465-475.
26. Salas M, Hofman A, Stricker B Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999, 149:981-983.
27. Meister R, Schaefer C Statistical methods for estimating the probability of spontaneous abortion in observational studies-analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol 2008, 26:31-35.
28. Boareto AC, Müller JC, de Araujo SL, et al. Study on the developmental toxicity of combined artesunate and mefloquine antimalarial drugs on rats. Reprod Toxicol 2012, 34:658-664.
29. Clark RL, Arima A, Makori N, et al. Artesunate: developmental toxicity and toxicokinetics in monkeys. Birth Defects Res B Dev Reprod Toxicol 2008, 83:418-434.
30. Laochan N, Zaloumis S, Imwong M, et al. Intervals to Plasmodium falciparum recurrence after anti-malarial treatment in pregnancy: a longitudinal prospective cohort. Malar J 2015, 14:221.
31. Manyando C, Njunju EM, Virtanen M, Hamed K, Gomes M Exposure to artemether-lumefantrine (Coartem®) in first trimester pregnancy in an observational study in Zambia. Malar J 2015, 14:77. Van geertruyden J-P.